Literature DB >> 2196774

Antianginal, hemodynamic and coronary vascular effects of captopril in stable angina pectoris.

H Ikram1, C J Low, T Shirlaw, C M Webb, A M Richards, I G Crozier.   

Abstract

A pilot study was performed to assess the short-term effects of intravenous captopril on anginal threshold and systemic and coronary hemodynamics in patients with stable angina pectoris. Twelve patients with documented coronary artery disease, stable angina pectoris and normal left ventricular function were studied by an incremental atrial pacing stress test before and after intravenous captopril (n = 8) or placebo (n = 4). There were no significant differences in the extent of coronary disease or left ventricular function between the 2 groups and resting plasma-renin levels were normal. Captopril increased the time to angina (14 +/- 4 to 9 +/- 5 minutes, p less than 0.05), increased heart rate at development of angina (126 +/- 7 to 142 +/- 7 beats/min, p less than 0.05) and tended to increase coronary blood flow (229 +/- 154 to 296 +/- 259 ml/min, p = 0.11) and decrease coronary vascular resistance (53 +/- 10 to 47 +/- 3 dynes s cm-5/1,000, p = 0.11) at peak stress without alteration in systemic hemodynamics. No significant changes were seen after placebo administration. Therefore, intravenous captopril appears to cause a short-term increase of coronary vascular reserve, and anginal threshold in patients with chronic stable angina. This effect appears to be independent of inhibition of the systemic renin-angiotensin system or systemic hemodynamic changes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196774     DOI: 10.1016/0002-9149(90)90581-k

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Angiotensin converting enzyme inhibitors in angina and myocardial infarction. What role will they play in the 1990s?

Authors:  G Ertl
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 2.  Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action?

Authors:  J D Rutherford
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

Review 3.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 4.  The renin-angiotensin system and coronary vasomotion.

Authors:  G Ertl; K Hu; W R Bauer; B Bauer
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 5.  Role of ACE inhibitors in hypertension complicated by vascular disease.

Authors:  G T McInnes
Journal:  Br Heart J       Date:  1994-09

Review 6.  Effects of ACE inhibitors on coronary haemodynamics and angina pectoris.

Authors:  M K Davies
Journal:  Br Heart J       Date:  1994-09

Review 7.  Current concepts: converting enzyme inhibitors in coronary artery disease.

Authors:  P Thürmann; N Rietbrock
Journal:  Clin Investig       Date:  1992-01

8.  Lack of effect of nitrates on exercise tolerance in patients with mild to moderate heart failure caused by coronary disease already treated with captopril.

Authors:  S Wieshammer; M Hetzel; J Hetzel; M Kochs; V Hombach
Journal:  Br Heart J       Date:  1993-07

Review 9.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 10.  Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.